| Literature DB >> 26445233 |
Barry Linnane1,2,3, Linda Kearse4,5, Nuala H O'Connell6,7, John Fenton8,9, Miranda G Kiernan10, Colum P Dunne11.
Abstract
BACKGROUND: Pseudomonas aeruginosa is a pathogen associated with cystic fibrosis that has potential to decrease lung function and cause respiratory failure. Paranasal sinuses are increasingly recognised as potential reservoirs for intermittent colonisation by P. aeruginosa. This case documents investigation and outcome of P. aeruginosa recurrence in a male paediatric patient over an eight year period. CASEEntities:
Mesh:
Substances:
Year: 2015 PMID: 26445233 PMCID: PMC4596362 DOI: 10.1186/s12890-015-0113-0
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Phenotypic profile of Pseudomonas aeruginosa isolates from a paediatric patient over n 8 year period
| Phenotypic classification | |||||
|---|---|---|---|---|---|
| Date specimen taken | Specimen cultured from (Location) | Gram staining + ve or -ve | Mucoid (+ or -) | Proteolytic (+/++/+++) | Siderophore producing (+/++/+++) |
| 11/08/06a | Cough Swab | - | - | ||
| 23/08/07c | Cough Swab | - | - | ||
| 07/08/08c,d | Cough Swab | - | - | ||
| 05/05/10b | Cough Swab | - | - | ||
| 14/12/10 | Cough Swab | - | + | ||
| 22/04/11b | Cough Swab | - | - | ||
| 10/04/12b,c,d | Cough Swab | - | - | ||
| 23/03/13 | Cough Swab | - | + | +++ | +++ |
| 06/06/13c | Cough Swab | - | + | ++ | + |
| 30/09/13 | Cough Swab | - | - | +++ | ++ |
| 20/12/13 | Cough Swab | - | + | + | + |
| 23/01/14e | Antral Washing | - | + | ++ | +++ |
| 11/09/14 | Antral Washing | - | - | + | + |
aFirst identification of Pseudomonas aeruginosa. b P. aeruginosa growth described as “scanty” by University Hospital Limerick microbiology laboratory. c Staphylococcus aureus also identified in addition to P. aeruginosa
d Haemophilus parainfluenzae also identified in addition to P. aeruginosa. e Pseudomonas fluorescens also identified in addition to P. aeruginosa
Where + = low, ++ = intermediate, +++ = high
Antimicrobial sensitivity profile for Pseudomonas aeruginosa from a paediatric patient over an 8 year period
| CLSI Guidelines | EUCAST Guidelines | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disk content (μg) | 2006 | 2007 | 2008 | 2010 | 2011 | 2012 | Disk content (μg) | 2013 | 2014 | |||||||
| 11/8 | 23/8 | 6/8 | 5/5 | 14/12 | 22/4 | 10/4 | 26/3 | 6/6 | 30/9 | 20/12 | 23/1 | 23/1a | 11/9a | |||
| Drug | ||||||||||||||||
| Ofloxacin | 5 | S | S | NT | NT | NT | NT | NT | 0 | NT | NT | NT | NT | NT | NT | NT |
| Pipercillin/ Tazobactum | 100/10 | S | S | S | S | S | S | S | 36 | S | S | S | S | S | R | S |
| Ceftazidime | 30 | S | S | S | S | S | S | S | 10 | S | S | S | S | S | S | S |
| Tobramycin | 10 | S | S | S | S | S | S | S | 10 | S | S | S | S | S | S | S |
| Ciprofloxacin | 5 | NT | S | NT | S | S | S | S | 5 | S | S | S | S | S | S | S |
| Amikacin | 30 | NT | S | NT | NT | NT | NT | NT | 30 | NT | NT | NT | NT | NT | NT | NT |
| Aztreoman | 30 | NT | S | NT | NT | NT | NT | S | 30 | S | I | I | I | I | I | I |
| Colistin (E-Test) | 10 | NT | S | NT | NT | NT | NT | NT | 10 | NT | NT | S | S | S | S | S |
| Imipenem | 10 | NT | S | NT | NT | NT | NT | NT | 10 | NT | NT | NT | NT | NT | NT | NT |
| Meropenem | 10 | NT | S | S | S | S | S | S | 10 | S | S | S | S | S | S | S |
S Susceptible, I Intermediate, R Resistant and NT Not Tested
a P. aeruginosa isolated from antral washing